Industry Research Reports

Home > Reports > Chemical & Material > Edaravone API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Edaravone API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Industry: Chemical & Material

Published Date: 2026-07-14

Pages: 135 Pages

Report ld: 6894578

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global market for Edaravone API was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.

Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral scleorosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properies, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects. Oral formulation of edaravone is currently under development.

The North American market for Edaravone API was valued at US$ million in 2025 and is projected to reach US$ million by 2032, at a CAGR of % from 2026 to 2032.

The Asia-Pacific market for Edaravone API was valued at $ million in 2025 and is projected to climb to US$ million by 2032, at a CAGR of % from 2026 to 2032.

The European market for Edaravone API was valued at $ million in 2025 and is projected to total US$ million by 2032, at a CAGR of % from 2026 to 2032.

The global key companies in the Edaravone API market include Dr. Reddy’s Laboratories Ltd., ChemWerth Inc, Medichem S.A, Solara Active Pharma Sciences, Neuland Laboratories, Jiangsu Haici Bio-Pharmaceutical Co., Ltd, etc. In 2025, the five largest players accounted for approximately % of revenue.

This report provides a comprehensive view of the global market for Edaravone API, covering total sales volume, sales revenue, pricing, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.

The Edaravone API market size, estimations, and forecasts are presented in terms of sales volume (Ton) and revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Edaravone API.

MARKET SEGMENTATION

By Company

Dr. Reddy’s Laboratories Ltd.
ChemWerth Inc
Medichem S.A
Solara Active Pharma Sciences
Neuland Laboratories
Jiangsu Haici Bio-Pharmaceutical Co., Ltd

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Purity≥98%
Purity<98%

Segment by Application

Edaravone Injection
Others

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the scope of the report and the global market size (value, volume, and price). It also summarizes market dynamics and Recent Developments; identifies key drivers and restraints; outlines challenges and risks for manufacturers; reviews relevant industry policies and U.S. tariff implications.

Chapter 2: Provides a detailed analysis of the Edaravone API manufacturers' competitive landscape—including pricing, sales and revenue shares, Recent Developments plans, and mergers and acquisitions (M&A).

Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 5: Presents Edaravone API sales and revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.

Chapter 6: Presents Edaravone API sales and revenue at the country level. It provides segmented data by Type and by Application for each country/region.

Chapter 7: Profiles key players, detailing the main companies' product sales, revenue, pricing, gross margin, product portfolios, Recent Developments, etc.

Chapter 8: Analyzes the industry value chain, including upstream suppliers and downstream applications/customers.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Edaravone API Product Introduction

1.2 Global Edaravone API Market Size Forecast

1.2.1 Global Edaravone API Sales Value (2021–2032)

1.2.2 Global Edaravone API Sales Volume (2021–2032)

1.2.3 Global Edaravone API Sales Price (2021–2032)

1.3 Edaravone API Market Trends & Drivers

1.3.1 Edaravone API Industry Trends

1.3.2 Edaravone API Market Drivers & Opportunities

1.3.3 Edaravone API Market Challenges

1.3.4 Edaravone API Market Restraints

1.3.5 Impact of U.S. Tariffs

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Edaravone API Players Revenue Ranking (2025)

2.2 Global Edaravone API Revenue by Company (2021–2026)

2.3 Global Edaravone API Sales Volume Ranking of Players (2025)

2.4 Global Edaravone API Sales Volume by Company (2021–2026)

2.5 Global Edaravone API Average Price by Company (2021–2026)

2.6 Key Manufacturers Edaravone API Manufacturing Base and Headquarters

2.7 Key Manufacturers Edaravone API Product Offerings

2.8 Key Manufacturers Start of Mass Production of Edaravone API

2.9 Edaravone API Market Competitive Analysis

2.9.1 Edaravone API Market Concentration Rate (2021–2026)

2.9.2 Global 5 and 10 Largest Manufacturers by Edaravone API Revenue in 2025

2.9.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Edaravone API revenue, 2025

2.10 Mergers & Acquisitions and Expansion

3 Segmentation Edaravone API Market Classification

3.1 Introduction by Type

3.1.1 Purity≥98%

3.1.2 Purity<98%

3.1.3 Global Edaravone API Sales Value by Type

3.1.3.1 Global Edaravone API Sales Value by Type (2021 vs 2025 vs 2032)

3.1.3.2 Global Edaravone API Sales Value, by Type (2021–2032)

3.1.3.3 Global Edaravone API Sales Value, by Type (%), 2021–2032

3.1.4 Global Edaravone API Sales Volume by Type

3.1.4.1 Global Edaravone API Sales Volume by Type (2021 vs 2025 vs 2032)

3.1.4.2 Global Edaravone API Sales Volume, by Type (2021–2032)

3.1.4.3 Global Edaravone API Sales Volume, by Type (%), 2021–2032

3.1.5 Global Edaravone API Average Price by Type (2021–2032)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Edaravone Injection

4.1.2 Others

4.2 Global Edaravone API Sales Value by Application

4.2.1 Global Edaravone API Sales Value by Application (2021 vs 2025 vs 2032)

4.2.2 Global Edaravone API Sales Value, by Application (2021–2032)

4.2.3 Global Edaravone API Sales Value, by Application (%), 2021–2032

4.3 Global Edaravone API Sales Volume by Application

4.3.1 Global Edaravone API Sales Volume by Application (2021 vs 2025 vs 2032)

4.3.2 Global Edaravone API Sales Volume, by Application (2021–2032)

4.3.3 Global Edaravone API Sales Volume, by Application (%), 2021–2032

4.4 Global Edaravone API Average Price by Application (2021–2032)

5 Segmentation by Region

5.1 Global Edaravone API Sales Value by Region

5.1.1 Global Edaravone API Sales Value by Region: 2021 vs 2025 vs 2032

5.1.2 Global Edaravone API Sales Value by Region (2021–2026)

5.1.3 Global Edaravone API Sales Value by Region (2027–2032)

5.1.4 Global Edaravone API Sales Value by Region (%), 2021–2032

5.2 Global Edaravone API Sales Volume by Region

5.2.1 Global Edaravone API Sales Volume by Region: 2021 vs 2025 vs 2032

5.2.2 Global Edaravone API Sales Volume by Region (2021–2026)

5.2.3 Global Edaravone API Sales Volume by Region (2027–2032)

5.2.4 Global Edaravone API Sales Volume by Region (%), 2021–2032

5.3 Global Edaravone API Average Price by Region (2021–2032)

5.4 North America

5.4.1 North America Edaravone API Sales Value, 2021–2032

5.4.2 North America Edaravone API Sales Value by Country (%), 2025 vs 2032

5.5 Europe

5.5.1 Europe Edaravone API Sales Value, 2021–2032

5.5.2 Europe Edaravone API Sales Value by Country (%), 2025 vs 2032

5.6 Asia Pacific

5.6.1 Asia Pacific Edaravone API Sales Value, 2021–2032

5.6.2 Asia Pacific Edaravone API Sales Value by Region (%), 2025 vs 2032

5.7 South America

5.7.1 South America Edaravone API Sales Value, 2021–2032

5.7.2 South America Edaravone API Sales Value by Country (%), 2025 vs 2032

5.8 Middle East & Africa

5.8.1 Middle East & Africa Edaravone API Sales Value, 2021–2032

5.8.2 Middle East & Africa Edaravone API Sales Value by Country (%), 2025 vs 2032

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Edaravone API Sales Value Growth Trends, 2021 vs 2025 vs 2032

6.2 Key Countries/Regions Edaravone API Sales Value and Sales Volume

6.2.1 Key Countries/Regions Edaravone API Sales Value, 2021–2032

6.2.2 Key Countries/Regions Edaravone API Sales Volume, 2021–2032

6.3 United States

6.3.1 United States Edaravone API Sales Value, 2021–2032

6.3.2 United States Edaravone API Sales Value by Type (%), 2025 vs 2032

6.3.3 United States Edaravone API Sales Value by Application, 2025 vs 2032

6.4 Europe

6.4.1 Europe Edaravone API Sales Value, 2021–2032

6.4.2 Europe Edaravone API Sales Value by Type (%), 2025 vs 2032

6.4.3 Europe Edaravone API Sales Value by Application, 2025 vs 2032

6.5 China

6.5.1 China Edaravone API Sales Value, 2021–2032

6.5.2 China Edaravone API Sales Value by Type (%), 2025 vs 2032

6.5.3 China Edaravone API Sales Value by Application, 2025 vs 2032

6.6 Japan

6.6.1 Japan Edaravone API Sales Value, 2021–2032

6.6.2 Japan Edaravone API Sales Value by Type (%), 2025 vs 2032

6.6.3 Japan Edaravone API Sales Value by Application, 2025 vs 2032

6.7 South Korea

6.7.1 South Korea Edaravone API Sales Value, 2021–2032

6.7.2 South Korea Edaravone API Sales Value by Type (%), 2025 vs 2032

6.7.3 South Korea Edaravone API Sales Value by Application, 2025 vs 2032

6.8 Southeast Asia

6.8.1 Southeast Asia Edaravone API Sales Value, 2021–2032

6.8.2 Southeast Asia Edaravone API Sales Value by Type (%), 2025 vs 2032

6.8.3 Southeast Asia Edaravone API Sales Value by Application, 2025 vs 2032

6.9 India

6.9.1 India Edaravone API Sales Value, 2021–2032

6.9.2 India Edaravone API Sales Value by Type (%), 2025 vs 2032

6.9.3 India Edaravone API Sales Value by Application, 2025 vs 2032

7 Company Profiles

7.1 Dr. Reddy’s Laboratories Ltd.

7.1.1 Dr. Reddy’s Laboratories Ltd. Company Information

7.1.2 Dr. Reddy’s Laboratories Ltd. Introduction and Business Overview

7.1.3 Dr. Reddy’s Laboratories Ltd. Edaravone API Sales, Revenue, Price and Gross Margin (2021–2026)

7.1.4 Dr. Reddy’s Laboratories Ltd. Edaravone API Product Offerings

7.1.5 Dr. Reddy’s Laboratories Ltd. Recent Developments

7.2 ChemWerth Inc

7.2.1 ChemWerth Inc Company Information

7.2.2 ChemWerth Inc Introduction and Business Overview

7.2.3 ChemWerth Inc Edaravone API Sales, Revenue, Price and Gross Margin (2021–2026)

7.2.4 ChemWerth Inc Edaravone API Product Offerings

7.2.5 ChemWerth Inc Recent Developments

7.3 Medichem S.A

7.3.1 Medichem S.A Company Information

7.3.2 Medichem S.A Introduction and Business Overview

7.3.3 Medichem S.A Edaravone API Sales, Revenue, Price and Gross Margin (2021–2026)

7.3.4 Medichem S.A Edaravone API Product Offerings

7.3.5 Medichem S.A Recent Developments

7.4 Solara Active Pharma Sciences

7.4.1 Solara Active Pharma Sciences Company Information

7.4.2 Solara Active Pharma Sciences Introduction and Business Overview

7.4.3 Solara Active Pharma Sciences Edaravone API Sales, Revenue, Price and Gross Margin (2021–2026)

7.4.4 Solara Active Pharma Sciences Edaravone API Product Offerings

7.4.5 Solara Active Pharma Sciences Recent Developments

7.5 Neuland Laboratories

7.5.1 Neuland Laboratories Company Information

7.5.2 Neuland Laboratories Introduction and Business Overview

7.5.3 Neuland Laboratories Edaravone API Sales, Revenue, Price and Gross Margin (2021–2026)

7.5.4 Neuland Laboratories Edaravone API Product Offerings

7.5.5 Neuland Laboratories Recent Developments

7.6 Jiangsu Haici Bio-Pharmaceutical Co., Ltd

7.6.1 Jiangsu Haici Bio-Pharmaceutical Co., Ltd Company Information

7.6.2 Jiangsu Haici Bio-Pharmaceutical Co., Ltd Introduction and Business Overview

7.6.3 Jiangsu Haici Bio-Pharmaceutical Co., Ltd Edaravone API Sales, Revenue, Price and Gross Margin (2021–2026)

7.6.4 Jiangsu Haici Bio-Pharmaceutical Co., Ltd Edaravone API Product Offerings

7.6.5 Jiangsu Haici Bio-Pharmaceutical Co., Ltd Recent Developments

8 Industry Chain Analysis

8.1 Edaravone API Industrial Chain

8.2 Edaravone API Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Key Suppliers of Raw Materials

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customer Analysis)

8.5 Sales Model and Sales Channelss

8.5.1 Edaravone API Sales Model

8.5.2 Sales Channels

8.5.3 Edaravone API Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Edaravone API Market Trends

Table 2. Edaravone API Market Drivers & Opportunities

Table 3. Edaravone API Market Challenges

Table 4. Edaravone API Market Restraints

Table 5. Global Edaravone API Revenue by Company (US$ Million), 2021–2026

Table 6. Global Edaravone API Revenue Market Share by Company (2021–2026)

Table 7. Global Edaravone API Sales Volume by Company (Ton), 2021–2026

Table 8. Global Edaravone API Sales Volume Market Share by Company (2021–2026)

Table 9. Global Market Edaravone API Price by Company (US$/Ton), 2021–2026

Table 10. Key Manufacturers Edaravone API Manufacturing Base and Headquarters

Table 11. Key Manufacturers Edaravone API Product Type

Table 12. Key Manufacturers Start of Mass Production of Edaravone API

Table 13. Global Edaravone API Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Tier (Tier 1, Tier 2, Tier 3), based on Edaravone API revenue, 2025

Table 15. Mergers & Acquisitions and Expansion Plans

Table 16. Global Edaravone API Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)

Table 17. Global Edaravone API Sales Value by Type (US$ Million), 2021–2026

Table 18. Global Edaravone API Sales Value by Type (US$ Million), 2027–2032

Table 19. Global Edaravone API Sales Market Share in Value by Type (2021–2026)

Table 20. Global Edaravone API Sales Market Share in Value by Type (2027–2032)

Table 21. Global Edaravone API Sales Volume by Type: 2021 vs 2025 vs 2032 (Ton)

Table 22. Global Edaravone API Sales Volume by Type (Ton), 2021–2026

Table 23. Global Edaravone API Sales Volume by Type (Ton), 2027–2032

Table 24. Global Edaravone API Sales Market Share in Volume by Type (2021–2026)

Table 25. Global Edaravone API Sales Market Share in Volume by Type (2027–2032)

Table 26. Global Edaravone API Price by Type (US$/Ton), 2021–2026

Table 27. Global Edaravone API Price by Type (US$/Ton), 2027–2032

Table 28. Global Edaravone API Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)

Table 29. Global Edaravone API Sales Value by Application (US$ Million), 2021–2026

Table 30. Global Edaravone API Sales Value by Application (US$ Million), 2027–2032

Table 31. Global Edaravone API Sales Market Share in Value by Application (2021–2026)

Table 32. Global Edaravone API Sales Market Share in Value by Application (2027–2032)

Table 33. Global Edaravone API Sales Volume by Application: 2021 vs 2025 vs 2032 (Ton)

Table 34. Global Edaravone API Sales Volume by Application (Ton), 2021–2026

Table 35. Global Edaravone API Sales Volume by Application (Ton), 2027–2032

Table 36. Global Edaravone API Sales Market Share in Volume by Application (2021–2026)

Table 37. Global Edaravone API Sales Market Share in Volume by Application (2027–2032)

Table 38. Global Edaravone API Price by Application (US$/Ton), 2021–2026

Table 39. Global Edaravone API Price by Application (US$/Ton), 2027–2032

Table 40. Global Edaravone API Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032

Table 41. Global Edaravone API Sales Value by Region (US$ Million), 2021–2026

Table 42. Global Edaravone API Sales Value by Region (US$ Million), 2027–2032

Table 43. Global Edaravone API Sales Value by Region (%), 2021–2026

Table 44. Global Edaravone API Sales Value by Region (%), 2027–2032

Table 45. Global Edaravone API Sales Volume by Region (Ton): 2021 vs 2025 vs 2032

Table 46. Global Edaravone API Sales Volume by Region (Ton), 2021–2026

Table 47. Global Edaravone API Sales Volume by Region (Ton), 2027–2032

Table 48. Global Edaravone API Sales Volume by Region (%), 2021–2026

Table 49. Global Edaravone API Sales Volume by Region (%), 2027–2032

Table 50. Global Edaravone API Average Price by Region (US$/Ton), 2021–2026

Table 51. Global Edaravone API Average Price by Region (US$/Ton), 2027–2032

Table 52. Key Countries/Regions Edaravone API Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032

Table 53. Key Countries/Regions Edaravone API Sales Value, (US$ Million), 2021–2026

Table 54. Key Countries/Regions Edaravone API Sales Value, (US$ Million), 2027–2032

Table 55. Key Countries/Regions Edaravone API Sales Volume, (Ton), 2021–2026

Table 56. Key Countries/Regions Edaravone API Sales Volume, (Ton), 2027–2032

Table 57. Dr. Reddy’s Laboratories Ltd. Company Information

Table 58. Dr. Reddy’s Laboratories Ltd. Introduction and Business Overview

Table 59. Dr. Reddy’s Laboratories Ltd. Edaravone API Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021–2026)

Table 60. Dr. Reddy’s Laboratories Ltd. Edaravone API Product Offerings

Table 61. Dr. Reddy’s Laboratories Ltd. Recent Developments

Table 62. ChemWerth Inc Company Information

Table 63. ChemWerth Inc Introduction and Business Overview

Table 64. ChemWerth Inc Edaravone API Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021–2026)

Table 65. ChemWerth Inc Edaravone API Product Offerings

Table 66. ChemWerth Inc Recent Developments

Table 67. Medichem S.A Company Information

Table 68. Medichem S.A Introduction and Business Overview

Table 69. Medichem S.A Edaravone API Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021–2026)

Table 70. Medichem S.A Edaravone API Product Offerings

Table 71. Medichem S.A Recent Developments

Table 72. Solara Active Pharma Sciences Company Information

Table 73. Solara Active Pharma Sciences Introduction and Business Overview

Table 74. Solara Active Pharma Sciences Edaravone API Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021–2026)

Table 75. Solara Active Pharma Sciences Edaravone API Product Offerings

Table 76. Solara Active Pharma Sciences Recent Developments

Table 77. Neuland Laboratories Company Information

Table 78. Neuland Laboratories Introduction and Business Overview

Table 79. Neuland Laboratories Edaravone API Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021–2026)

Table 80. Neuland Laboratories Edaravone API Product Offerings

Table 81. Neuland Laboratories Recent Developments

Table 82. Jiangsu Haici Bio-Pharmaceutical Co., Ltd Company Information

Table 83. Jiangsu Haici Bio-Pharmaceutical Co., Ltd Introduction and Business Overview

Table 84. Jiangsu Haici Bio-Pharmaceutical Co., Ltd Edaravone API Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021–2026)

Table 85. Jiangsu Haici Bio-Pharmaceutical Co., Ltd Edaravone API Product Offerings

Table 86. Jiangsu Haici Bio-Pharmaceutical Co., Ltd Recent Developments

Table 87. Key Raw Materials Lists

Table 88. Key Suppliers of Raw Materials Lists

Table 89. Edaravone API Downstream Customers

Table 90. Edaravone API Distributors List

Table 91. Research Programs/Design for This Report

Table 92. Key Data Information from Secondary Sources

Table 93. Key Data Information from Primary Sources

List of Figures

Figure 1. Edaravone API Product Picture

Figure 2. Global Edaravone API Sales Value, 2021 vs 2025 vs 2032 (US$ Million)

Figure 3. Global Edaravone API Sales Value (US$ Million), 2021–2032

Figure 4. Global Edaravone API Sales Volume (Ton), 2021–2032

Figure 5. Global Edaravone API Sales Price (US$/Ton), 2021–2032

Figure 6. Edaravone API Report Years Considered

Figure 7. Global Edaravone API Players Revenue Ranking (US$ Million), 2025

Figure 8. Global Edaravone API Sales Volume Ranking of Players (Ton), 2025

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Edaravone API Revenue in 2025

Figure 10. Edaravone API Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 11. Purity≥98% Picture

Figure 12. Purity<98% Picture

Figure 13. Global Edaravone API Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global Edaravone API Sales Value Market Share by Type, 2025 & 2032

Figure 15. Global Edaravone API Sales Volume by Type (Ton), 2021 vs 2025 vs 2032

Figure 16. Global Edaravone API Sales Volume Market Share by Type, 2025 & 2032

Figure 17. Global Edaravone API Price by Type (US$/Ton), 2021–2032

Figure 18. Product Picture of Edaravone Injection

Figure 19. Product Picture of Others

Figure 20. Global Edaravone API Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032

Figure 21. Global Edaravone API Sales Value Market Share by Application, 2025 & 2032

Figure 22. Global Edaravone API Sales Volume by Application (Ton), 2021 vs 2025 vs 2032

Figure 23. Global Edaravone API Sales Volume Market Share by Application, 2025 & 2032

Figure 24. Global Edaravone API Price by Application (US$/Ton), 2021–2032

Figure 25. North America Edaravone API Sales Value (US$ Million), 2021–2032

Figure 26. North America Edaravone API Sales Value by Country (%), 2025 vs 2032

Figure 27. Europe Edaravone API Sales Value (US$ Million), 2021–2032

Figure 28. Europe Edaravone API Sales Value by Country (%), 2025 vs 2032

Figure 29. Asia Pacific Edaravone API Sales Value (US$ Million), 2021–2032

Figure 30. Asia Pacific Edaravone API Sales Value by Region (%), 2025 vs 2032

Figure 31. South America Edaravone API Sales Value (US$ Million), 2021–2032

Figure 32. South America Edaravone API Sales Value by Country (%), 2025 vs 2032

Figure 33. Middle East & Africa Edaravone API Sales Value (US$ Million), 2021–2032

Figure 34. Middle East & Africa Edaravone API Sales Value by Country (%), 2025 vs 2032

Figure 35. Key Countries/Regions Edaravone API Sales Value (%), 2021–2032

Figure 36. Key Countries/Regions Edaravone API Sales Volume (%), 2021–2032

Figure 37. United States Edaravone API Sales Value (US$ Million), 2021–2032

Figure 38. United States Edaravone API Sales Value by Type (%), 2025 vs 2032

Figure 39. United States Edaravone API Sales Value by Application (%), 2025 vs 2032

Figure 40. Europe Edaravone API Sales Value (US$ Million), 2021–2032

Figure 41. Europe Edaravone API Sales Value by Type (%), 2025 vs 2032

Figure 42. Europe Edaravone API Sales Value by Application (%), 2025 vs 2032

Figure 43. China Edaravone API Sales Value (US$ Million), 2021–2032

Figure 44. China Edaravone API Sales Value by Type (%), 2025 vs 2032

Figure 45. China Edaravone API Sales Value by Application (%), 2025 vs 2032

Figure 46. Japan Edaravone API Sales Value (US$ Million), 2021–2032

Figure 47. Japan Edaravone API Sales Value by Type (%), 2025 vs 2032

Figure 48. Japan Edaravone API Sales Value by Application (%), 2025 vs 2032

Figure 49. South Korea Edaravone API Sales Value (US$ Million), 2021–2032

Figure 50. South Korea Edaravone API Sales Value by Type (%), 2025 vs 2032

Figure 51. South Korea Edaravone API Sales Value by Application (%), 2025 vs 2032

Figure 52. Southeast Asia Edaravone API Sales Value (US$ Million), 2021–2032

Figure 53. Southeast Asia Edaravone API Sales Value by Type (%), 2025 vs 2032

Figure 54. Southeast Asia Edaravone API Sales Value by Application (%), 2025 vs 2032

Figure 55. India Edaravone API Sales Value (US$ Million), 2021–2032

Figure 56. India Edaravone API Sales Value by Type (%), 2025 vs 2032

Figure 57. India Edaravone API Sales Value by Application (%), 2025 vs 2032

Figure 58. Edaravone API Industrial Chain

Figure 59. Edaravone API Manufacturing Cost Structure

Figure 60. Channels of Distribution (Direct Sales, and Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Edaravone API market? zhanKai

The top companies in the global Edaravone API market are Dr. Reddy’s Laboratories Ltd.、ChemWerth Inc、Medichem S.A.

Related Reports

Global Edaravone API Market Research Report 2026
The global Edaravone API market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-04-21
Pages: 129
USD 2900.00
(Single User License)
Global Edaravone API Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Edaravone API market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-10-22
Pages: 149
USD 4900.00
(Single User License)
Edaravone API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Edaravone API was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-15
Pages: 94
USD 3950.00
(Single User License)
Global Edaravone API Market Research Report 2025
The global market for Edaravone API was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-15
Pages: 88
USD 2900.00
(Single User License)
Global Edaravone API Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Edaravone API market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-15
Pages: 77
USD 4250.00
(Single User License)
Global Edaravone API Market Insights, Forecast to 2030
Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral scleorosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properies, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects. Oral formulation of edaravone is currently under development.
Published Date: 2024-04-15
Pages: 93
USD 4900.00
(Single User License)
Edaravone API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral scleorosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properies, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects. Oral formulation of edaravone is currently under development.
Published Date: 2024-02-23
Pages: 96
USD 3950.00
(Single User License)
Global Edaravone API Market Research Report 2024
Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral scleorosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properies, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects. Oral formulation of edaravone is currently under development.
Published Date: 2024-01-10
Pages: 88
USD 2900.00
(Single User License)

Global Edaravone API Market Research Report 2026
The global Edaravone API market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-04-21
Pages: 129
USD 2900.00 (Single User License)
Global Edaravone API Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Edaravone API market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-10-22
Pages: 149
USD 4900.00 (Single User License)
Edaravone API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Edaravone API was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-15
Pages: 94
USD 3950.00 (Single User License)
Global Edaravone API Market Research Report 2025
The global market for Edaravone API was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-15
Pages: 88
USD 2900.00 (Single User License)
Global Edaravone API Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Edaravone API market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-15
Pages: 77
USD 4250.00 (Single User License)
Global Edaravone API Market Insights, Forecast to 2030
Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral scleorosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properies, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects. Oral formulation of edaravone is currently under development.
Published: 2024-04-15
Pages: 93
USD 4900.00 (Single User License)
Edaravone API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral scleorosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properies, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects. Oral formulation of edaravone is currently under development.
Published: 2024-02-23
Pages: 96
USD 3950.00 (Single User License)
Global Edaravone API Market Research Report 2024
Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral scleorosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properies, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects. Oral formulation of edaravone is currently under development.
Published: 2024-01-10
Pages: 88
USD 2900.00 (Single User License)